1. Home
  2. Directory
  3. Alabama
  4. Atmore
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1821032012

DR. JOHN TAYLOR COOPER O.D.
Prescription History 1821032012
Optometrist in Atmore, AL

NPI Status: Active since June 16, 2006

Contact Information

212 S MAIN ST
ATMORE, AL
ZIP 36502
Phone: (251) 368-8558

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JOHN TAYLOR COOPER O.D., an active Optometrist specialist practicing in Atmore, AL. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 301 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 141 claims alone.

Medication Index

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 37
30-Day Fills 62.5
Days Supply 1,875
AL State Average Benchmarks
Peer Average Claims100.0
Peer Average 30-Day Fills194.0
Peer Average Days Supply5,793
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.0% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,389.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$37.54

State Avg Cost Per Claim

$35.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 141
30-Day Fills 357.4
Days Supply 10,631
AL State Average Benchmarks
Peer Average Claims169.0
Peer Average 30-Day Fills289.9
Peer Average Days Supply8,250
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,134.27 across this reporting matrix range.

Provider Avg Cost Per Claim

$50.60

State Avg Cost Per Claim

$23.22

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 42
30-Day Fills 42.0
Days Supply 470
AL State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills49.1
Peer Average Days Supply770
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $675.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.08

State Avg Cost Per Claim

$15.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 11
30-Day Fills 27.0
Days Supply 810
AL State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills71.1
Peer Average Days Supply2,111
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.1% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,022.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,638.44

State Avg Cost Per Claim

$1,010.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Timolol Maleate

Generic Formulation: Timolol MaleateSpecialty: Optometry
Provider Metrics Summary
Total Claims 35
30-Day Fills 87.0
Days Supply 2,591
AL State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills136.5
Peer Average Days Supply4,008
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 50.7% less volume than the regional standard for practitioners inside AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $613.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.52

State Avg Cost Per Claim

$26.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A beta-adrenergic antagonist that is similar in action to PROPRANOLOL; the levo-isomer is more active. Timolol has been proposed as an anti-hypertensive, anti-arrhythmic, anti-angina, and anti-glaucoma agent. It is also used in the treatment of MIGRAINE DISORDERS and tremor.

Therapeutic Applications

This medication is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers.

Tobramycin-Dexamethasone

Generic Formulation: Tobramycin/DexamethasoneSpecialty: Optometry
Provider Metrics Summary
Total Claims 35
30-Day Fills 35.0
Days Supply 457
AL State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.3
Peer Average Days Supply529
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across AL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,155.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$61.59

State Avg Cost Per Claim

$80.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A topical preparation of tobramycin and dexamethasone that is used for treating or preventing superficial bacterial infections of the eye.

Therapeutic Applications

This medication is used to treat or prevent eye infections. This medication contains two drugs. Tobramycin belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. Dexamethasone belongs to a class of drugs called corticosteroids. It works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JOHN TAYLOR COOPER O.D. provides transparency into local medical care patterns within Atmore, AL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.